newsfilter
← Latest News
GlobeNewswire·

Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in